46 related articles for article (PubMed ID: 38608069)
1. A Five-gene Signature based on MicroRNA for Predicting Prognosis and Immunotherapy in Stomach Adenocarcinoma.
Wang T; Chen P; Li T; Li J; Zhao D; Meng F; Zhao Y; Zheng Z; Liu X
Curr Med Chem; 2024; 31(17):2378-2399. PubMed ID: 38310388
[TBL] [Abstract][Full Text] [Related]
2. A novel copper metabolism-related signature model for predicting the prognosis, target drugs, and immunotherapy in stomach adenocarcinoma.
Zhuang K; Tang S; Feng H; Zhang J; Liu Y; Liu Y; Su Y; Yu J; Huang Z
Genes Dis; 2024 Sep; 11(5):101102. PubMed ID: 38774913
[No Abstract] [Full Text] [Related]
3. Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction.
Zhang Y; Zeng L; Lin D; Chang G; Zeng Y; Xia Y
Front Endocrinol (Lausanne); 2022; 13():1076521. PubMed ID: 36726460
[TBL] [Abstract][Full Text] [Related]
4. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract][Full Text] [Related]
5. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.
Li F; Feng Q; Tao R
Medicine (Baltimore); 2024 Mar; 103(10):e37314. PubMed ID: 38457593
[TBL] [Abstract][Full Text] [Related]
6. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract][Full Text] [Related]
7. Single-cell data revealed CD14-type and FCGR3A-type macrophages and relevant prognostic factors for predicting immunotherapy and prognosis in stomach adenocarcinoma.
Li M; Lu M; Li J; Gui Q; Xia Y; Lu C; Shu H
PeerJ; 2024; 12():e16776. PubMed ID: 38274323
[TBL] [Abstract][Full Text] [Related]
8. Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma.
Liu Y; Zhang L; Lei X; Yin X; Liu S
Aging (Albany NY); 2023 Oct; 15(20):11389-11411. PubMed ID: 37862109
[TBL] [Abstract][Full Text] [Related]
9. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
Feng Q; Lu H; Wu L
PLoS One; 2023; 18(9):e0291645. PubMed ID: 37725627
[TBL] [Abstract][Full Text] [Related]
10. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Luo Y; Ye Y; Chen Y; Zhang C; Sun Y; Wang C; Ou J
Front Immunol; 2023; 14():1140993. PubMed ID: 36993976
[TBL] [Abstract][Full Text] [Related]
11. Role of ROR2 in promoting gastric cancer metastasis by enhancing c-JUN-mediated MMP3 transcription.
Ge X; Lin F; Wu Z; Lin Y; Tang W; McKay MJ; Sahu A; Lino-Silva LS; Tseng J; Li J
Ann Transl Med; 2022 Oct; 10(20):1117. PubMed ID: 36388837
[TBL] [Abstract][Full Text] [Related]
12. Degradome-focused RNA interference screens to identify proteases important for breast cancer cell growth.
Hölzen L; Syré K; Mitschke J; Brummer T; Miething C; Reinheckel T
Front Oncol; 2022; 12():960109. PubMed ID: 36313646
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinating enzyme PSMD14 facilitates gastric carcinogenesis through stabilizing PTBP1.
Li J; Li Y; Xu F; Sun B; Yang L; Wang H
Exp Cell Res; 2022 Jun; 415(2):113148. PubMed ID: 35405117
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
